• Better life with AmoyDx
    more
  • Better life with AmoyDx
    more
  • AmoyDx won the Second Prize of National Scientific and Technological Progress Award
    more
  • Better life with AmoyDx
    more
Scroll

ABOUT AMOYDX

Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. 

more
Better Life with AmoyDx

Latest News

Latest News more
21 /Feb

AmoyDx® PD-L1 (E1L3N) assay gained the priority recommendation from Chinese expert consensus

The AmoyDx® PD-L1 (E1L3N) assay (NMPA approval number 20223400313) was prioritized as companion diagnostics for Pembrolizumab.

06 /Feb

AmoyDx has successfully held the 2023 Distributors Annual Meeting at the headquarter in Xiamen, China, on January 22-23, 2024

The 2023 Distributors Annual Meeting has been successfully hosted at the headquarter in Xiamen, China, on January 22-23, 2024. The event, attended by overseas colleagues and distributors worldwide, achieved notable success and provided a platform for a fo

13 /Nov

Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer

AmoyDx announced multiple collaborations with AstraZeneca and Pfizer during the 2023 China International Import Expo (CIIE), held on November 5-10 in Shanghai China. These partnerships aim to jointly promote the development of precision diagnostics

03 /Nov

AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics

National Medical Products Administration (NMPA) granted approval to AmoyDx® Microsatellite Instability (MSI) Detection Kit

more

New Products

new product release

    New Products

    new product release
    • Pan Lung Cancer PCR Panel

    • HANDLE Classic NGS Panel

    • HRD Focus Panel

    • BRCA Pro Panel

    • PLC Pan Lung Cancer PCR Panel
      01
    • Classic HANDLE Classic NGS Panel
      02
    • HRD HRD Focus Panel
      03
    • BRCA Pro BRCA Pro Panel
      04
    1. 01
    2. 02
    3. 03
    4. 04
    • Pan Lung Cancer PCR Panel

    • HANDLE Classic NGS Panel

    • HRD Focus Panel

    • BRCA Pro Panel

    • PLC Pan Lung Cancer PCR Panel
      01
    • Classic HANDLE Classic NGS Panel
      02
    • HRD HRD Focus Panel
      03
    • BRCA Pro BRCA Pro Panel
      04
    1. 01
    2. 02
    3. 03
    4. 04
    • Pan Lung Cancer PCR Panel

    • HANDLE Classic NGS Panel

    • HRD Focus Panel

    • BRCA Pro Panel

    • PLC Pan Lung Cancer PCR Panel
      01
    • Classic HANDLE Classic NGS Panel
      02
    • HRD HRD Focus Panel
      03
    • BRCA Pro BRCA Pro Panel
      04
    1. 01
    2. 02
    3. 03
    4. 04
    • Pan Lung Cancer PCR Panel

    • HANDLE Classic NGS Panel

    • HRD Focus Panel

    • BRCA Pro Panel

    • PLC Pan Lung Cancer PCR Panel
      01
    • Classic HANDLE Classic NGS Panel
      02
    • HRD HRD Focus Panel
      03
    • BRCA Pro BRCA Pro Panel
      04
    1. 01
    2. 02
    3. 03
    4. 04
  1. NGS
  2. PCR
  3. FISH
  4. Extraction

ESMO Asia

https://www.esmo.org/meetings/esmo-asia-congress-2022

December 2-4, 2022
meet us

AMP

https://www.amp.org/events/amp-events-calendar/calendar/amp-2022-annual-meeting-expo/

November 3-5, 2022
  • Stock Info

    Stock info
  • 22.82 +%1.42
    Stock code:300685 Real-time data
  • View details
Inquiry
* Required information
Manage your account info
Change your password